Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2014-01-17
Original market date: See footnote 1
2014-01-17
Product name:
GIOTRIF
DIN:
02415666
Product Monograph/Veterinary Labelling:
Date:
2019-06-06
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
5180 South Service Road
Burlington
Ontario
Canada
L7L 5H4
Class:
Human
Dosage form(s):
Tablet
Route(s) of administration:
Oral
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01EB03 AFATINIB
Active ingredient group (AIG) number:See footnote5
0154930001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| AFATINIB (AFATINIB DIMALEATE) | 20 MG |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.
Application information
Related information
Contact us
"Page details"
- Date modified: